Background/Aims: Tr1 cells can induce peripheral tolerance to self-and foreign antigens, and have been developed as a therapeutic tool for the induction of tolerance to transplanted tissue. We explored the feasibility of generating Tr1 cells by using IL-10 gene-modified recipient DCs (DC LV-IL-10 ) to stimulate donor naive CD4 + T cells. We also investigated some biological properties of Tr1 cells. Methods: DC LV-IL-10 were generated through DCs transduced with a lentivirus vector carrying the IL-10 gene, and Tr1 cells were produced by using DC LV-IL-10 to stimulate naive CD4 + T cells. The effects of Tr1 cells on T-cell proliferation and the occurrence of graft versus host disease (GVHD) following allogeneic stem-cell transplantation (allo-HSCT) were investigated. Results: The DC LV-IL-10 -induced Tr1 cells co-expressed LAG-3 and CD49b. Moreover, they also expressed CD4, CD25, and IL-10, but not Foxp3, and secreted significantly higher levels of IL-10 (1,729.36 ± 185.79 pg/mL; P < 0.001) and INF-γ (1,524.48 ± 168.65 pg/mL; P < 0.01) than the control T cells upon the stimulation by allogeneic DCs. Tr1 cells markedly suppressed T-lymphocyte proliferation and the mixed lymphocytic response (MLR) in vitro. The mice used in the allo-HSCT model had longer survival times and lower clinical and pathological GVHD scores than the control mice. Conclusion: IL-10 gene-modified DCinduced Tr1 cells may be used as a potent cellular therapy for the prevention of GVHD after allo-HSCT.
Introduction
T regulatory cells (Tregs) play a crucial role in the induction of peripheral tolerance to self-and foreign antigens. Numerous studies have demonstrated that Tregs are involved in the immunological dysregulation that underlies autoimmune diseases, chronic inflammatory diseases, and certain immunological complications of transplantation. Tregs are known to suppress the proliferation and effector functions of several different cell types, including T cells, B cells, natural killer (NK) cells, and antigen (Ag)-presenting cells (APCs) [1] . Tregs are also involved in immune homeostasis, regulation of inflammation, establishment and maintenance of immune tolerance, and prevention of graft versus host disease (GVHD) following an allogeneic hematopoietic stem cell transplant (allo-HSCT) [2, 3] . Tregs are divided into two categories: i) natural Tregs (nTregs), derived from the thymus and ii) adaptive or induced Tregs (aTregs or iTregs) induced outside the thymus in the presence of an antigen (Ag) and tolerogenic conditions. Tr1 cells comprise the main subset of Tregs.
The nTregs constitutively express CD4, CD25 and Foxp3, protect self-tolerance, and prevent autoimmunity [4] . However, the paucity of nTregs tends to impede investigations into their applications in both animal models and clinical studies. There are also some obstacles to expanding nTregs in vitro. First, other types of T cells expand preferentially in culture [5] . Second, the immunosuppressive function of nTregs is not Ag-specific [6] , and high nTreg to effector CD4 + T cell ratios (usually > 1:1) are needed to prevent GVHD [7] . In some cases, the large number of nTregs required to prevent GVHD can be impossible to achieved in humans [8] . Third, human nTregs often display unstable inhibitory activity in an ex-vivo environment, which makes them unsuitable for use in some preclinical models [9] .
In contrast to nTregs, Tr1 cells specifically co-express CD49b and LAG-3 [10] . Moreover, they also express CD4 and CD25, but not Foxp3. Upon activation, Tr1 cells modulate immune suppression mainly by secreting high levels of interleukin (IL)-10 and transforming growth factor (TGF)-β [11] [12] [13] . A previous study showed that Tr1 cells can mediate immune suppression by killing antigen presenting cells (APCs) via a perforin/granzyme-dependent process that requires major histocompatibility complex (MHC) class I recognition [14] . Because Tr1 cells provide tolerance to foreign antigens, they also play an important role in organ transplantation.
Many protocols for the in vitro induction of Tr1 cells describe a process in which the Tr1 cells are induced in the presence of either recombinant IL-10 and IFN-γ [15] or recombinant TGF-β and IL-27 [16] . Tr1 cells can also be generated by a single stimulation with IL-10-treated tolerogenic DCs [17] . However, only a minority of the Tr1 cells generated with most protocols produce IL-10. The main impediment to obtaining Tr1 cells for use in clinical applications such as cell therapy is the presence of contaminating effector T-cells in the resulting cell population. As an alternative method for obtaining a large and homogeneous population of Tr1 cells, lentivirus-mediated human IL-10 gene transfer has been used to convert conventional T cells into Tr1-like cells, which mirror the phenotype and function of Tr1 cells, and can suppress or prevent transplant rejection and GVHD. However, an important limitation of this method is that the generated Tr1-like cells cannot acquire autoantigen specificity [18] .
We previously induced Tr1 cells by stimulating transgenic OT II mouse-derived naive CD4 + T cells with IL-10-expressing adenovirus (AdV IL-10 )-transfected and ovalbumin (OVA)-pulsed dendritic cells (DC OVA/IL-10 ). That study demonstrated that both in vitro and in vivo, DC OVA/IL-10 -stimulated CD4 + Tr1 cells acquired OVA peptide MHC class I (pMHC I), which targeted the suppressive effect of CD4 + Tr1 cells [12] . This targeting led to an ~ 700% enhancement in the suppression of DC OVA -induced CD8 + T cell responses and the immune response against OVA-expressing murine B16 melanoma cells, when compared with the responses shown by analogous CD4 + Tr1 cells without acquired pMHC I [12] . Therefore, we hypothesized that Tr1 cells could be generated through IL-10 genemodified recipient DCs by stimulating donor naive CD4 + T cells. Moreover, we also hypothesized that the presence of recipient pMHC I on Tr1 cells should enhance their suppressive effect towards recipient cells. If so, an infusion of these Tr1 cells might induce transplant tolerance and prevent GVHD after allogeneic transplantation. In this study, we designed an experiment to explore the feasibility of using IL-10 gene-modified DCs to induce and expand Tr1 cells in vitro. We also assessed the immunosuppressive effects of the newly expanded Tr1 cells both in vitro and in vivo. Indeed, for the first time, we investigated the effects of in vitro-generated Tr1 cells on the incidence and severity of GVHD after an allo-HSCT. Our data suggest that Tr1 cells generated with IL-10 gene-modified DCs can effectively inhibit T cell proliferation and the mixed lymphocyte reaction (MLR) in vitro, and also reduce the occurrence of GVHD in mice after a transplant.
Materials and Methods
Animal studies C57BL/6 (H-2kb) and BALB/c (H-2kd) mice (age, 8-10 weeks) were purchased from Slac Laboratory Animal Co, Ltd. (Shanghai, China), and housed under specific pathogen-free conditions. All animal experiments were conducted according to guidelines published by The Ethics Committee of Xinhua Hospital Affiliated with the Shanghai Jiao Tong University School of Medicine. The protocols used in this study were approved by the Ethics Committee of Xinhua Hospital affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai China.
Cell culture and reagents RPMI-1640 medium, fetal bovine serum (FBS), recombinant mouse granulocyte-macrophage colonystimulating factor (rmGM-CSF), recombinant mouse interleukin (rmIL)-4 and rmIL-2 were purchased from PeproTech (PeproTech; Shanghai, China).
Lentiviral IL-10 vector construction and transduction into dendritic cells
The murine IL-10 gene was amplified by the polymerase chain reaction (PCR) performed with the following primers: forward: 5'-ACACCTCGAGATGCCTGGCTCAGCACTGC-3′ and reverse: 5′-ATTAG CGGCCGCTTATTTGTCGTCATCATCCTT-3′. The purified IL-10 gene fragment was cloned into the pHBLV-CMV-IRES-ZS Green plasmid (Hanbio Co., Ltd; Shanghai, China) using XhoI and NotI restriction sites. Lipofilter™ (Hanbio; Shanghai, China) was used to co-transfect the recombinant plasmid containing the IL-10 gene and green fluorescent protein (GFP) gene into 293T cells with a packaging plasmid (pSPAX2) and pMD2G envelop plasmid. Next, the virus particles were harvested from the cell supernatant and designated as LV-IL-10. Additionally, a control vector expressing GFP was constructed and designated as LV-GFP.
Bone marrow (BM)-derived DCs were generated as previously described [12] . Briefly, BM cells were isolated from the femora and tibiae of normal BALB/c mice, and the red blood cells were removed with 0.84% ammonium chloride. The remaining cells were plated using RPMI-1640 medium containing 10% FBS, 20 ng/mL rmGM-CSF, and 20 ng/mL rmIL-4 (Day 0). On day 3, the non-adherent granulocytes and T and B cells were gently dislodged and fresh medium was added. On day 5, the loosely adherent proliferating DC aggregates were removed and re-plated using the previously described culture medium containing 1 µg/ mL lipopolysaccharides (LPS) (Sigma; Shanghai, China) and cultured until day 6, when the non-adherent DCs were collected. The collected DCs were then transduced with LV-GFP or LV-IL-10 overnight at 37℃ with a multiplicity of infection of 100. GFP expression in the transduced DCs was detected by fluorescence microscopy at 24 hours after transduction, and the GFP-positive cells were sorted by flow cytometry. The purified GFP-positive DCs transduced with LV-GFP or LV-IL-10 were designated as DC GFP or DC LV-IL-10 , respectively. 
Preparation of DC LV-IL-10 -induced Tr1 cells

Flow cytometry
Expression of CD11c and CD83 on DC GFP and DC LV-IL-10 , and expression of CD49b, LAG3, CD4, CD25, Foxp3 and IL-10 on T DC , T GFP or Tr1 cells were detected by flow cytometry. Staining for CD11c, CD83, CD49b, LAG3, CD4, and CD25 on the cell surface was accomplished by incubating individual aliquots of cells on ice with fluorochrome-conjugated antibodies (eBioscience; Shanghai, China) for 30 min. For intracellular staining of Foxp3, Tr1 cells were fixed and permeabilized, and then stained with FITC-conjugated antiFoxp3 monoclonal antibodies (eBioscience; Shanghai, China). For assays of the intracellular cytokines IL-10, Tr1 cells were treated with Cell Stimulation Cocktail (2 µL/mL) for 5 h at 37℃ in the presence of 2 µL/mL Protein Transport Inhibitor Cocktail, and then permeabilized prior to staining with fluorescent dye-labeled anti-cytokine antibodies (eBioscience; Shanghai, China). Fluorescence-activated cell sorting (FACS) analyses for detection of various cell markers and cytokines were performed with a BD Canto II flow cytometer (Becton-Dickinson Biosciences, Shanghai, China).
RNA isolation and real-time PCR
To examine the levels of IL-10 mRNA expression in DC LV-IL-10 , total RNA was extracted from DCs, DC GFP and DC LV-IL-10 using TRIzol reagent (Takara; Liaoning, China); after which, a PrimeScript RT Master Mix kit (Takara Liaoning, China) was used to reverse transcribe 1 µg of total RNA into cDNA. Real-time PCR array analysis was performed with a SYBR Premix Ex TaqTM Kit (Takara; Liaoning, China) in a total volume of 20 µL. Each reaction mixture contained 2 µL of cDNA primers (0.2 mM each), 10 µL of SYBR Green, and 0.4 µL of Rox Dye II. The PCR conditions were 95°C for 30 s, followed by 40 cycles of 95°C for 5 s and 60°C for 34 s, with a final dissociation stage. The PCR samples were then analyzed using an ABI 7500 detector (Applied Biosystems; Foster City, CA, USA). The numbers of target genes were determined and normalized to the amount of GAPDH cDNA, which served as an internal standard (Sangon Biotech; Shanghai, China). The primers used for IL-10 were: forward: 5-GGACAACATACTGCTAACCGACTC-3 and reverse: 5-TGGGGCATCACTTCTACC-3 (Sangon Biotech; Shanghai, China).
ELISA
To detect IL-10, IL-6, TNF-α, and IL-12p70 levels in the DCs, DC GFP and DC LV-IL-10 , these cells were adjusted to concentrations 1 × 10 6 cells/mL and activated with 200 ng/mL of LPS plus 50 ng/mL of rmIFN-γ (Sigma; Shanghai, China) for 48 h. The supernatants were then collected for analysis. The levels of IL-10, IL-6, TNF-α, and IL-12p70 were measured with an ELISA kit (R&D Systems; Shanghai, China) according to the manufacturer's instructions.
To detect IL-10, INF-γ, IL-2, and IL-4 secreted by T DC , T GFP and Tr1 cells, these cells (1 × 10 6 cells/well) were stimulated with irradiated (40 Gy) BM-derived DCs (5 × 10 5 cells/well) obtained from BALB/c mice for 48 h. Next, the supernatants were harvested and the levels of IL-10, INF-γ, IL-2, and IL-4 were measured with an ELISA kit (R&D Systems; Shanghai, China) according to the manufacturer's instructions.
Briefly, microtiter plates were coated overnight at room temperature with mouse monoclonal antibodies (the capture antibody); after which, the wells were blocked for 1 h with PBS containing 1% FBS and then washed four times with 0.05% Tween-20 in PBS. Triplicate standards and samples were added to adjacent wells and incubated for 2 h at room temperature. After incubation, the wells were washed and the detection antibodies were added. After 2 h, the wells were washed again, and incubated with a horse radish peroxidase (HRP)-conjugated antibody in 1% FBS/PBS. Next, the plates were washed four times and incubated for 30 min with the substrate (0.0125% tetramethylbenzidine/0.008% H 2 O 2 in citrate buffer, pH 5). Color development was terminated by addition of 2 M H 2 SO 4 . The optical density of each well was measured with an ELISA reader, and the cytokine concentration in each well was calculated using a double standard curve (R&D System, Shanghai, China). 
Proliferation and suppression of T cells
Allogeneic bone marrow transplantation (BMT) animal study
For allogeneic BMTs, bone marrow cells (BMCs) and SCs were harvested from donor mice (C57BL/6). The harvested were then resuspended in RPMI-1640 medium containing 10% FBS and 1% penicillin/ streptomycin and adjusted to suitable cell concentrations. Recipient mice (BALB/c) were given a lethal dose of radiation (8 Gy) [18] and then intravenously transplanted with donor BMCs (1 × 10 ). Survival of the mice after BMT was monitored daily for 50 days. Individual clinical indicators of GVHD, including each animal's weight, posture, activity, fur texture, and skin integrity, received a weekly score ranging from 0 to 2 [20, 21] . On day 14 after BMT, the mice were sacrificed for a histopathology evaluation of GVHD. Samples of skin, liver, intestine, and lung tissue were fixed in 10% formalin and embedded in paraffin. Sections for histology (5 µm) were stained with hematoxylin and eosin and scored for GVHD [22] .
Statistical analysis
All statistical analyses were performed using IBM SPSS Statistics for Windows, Version 19.0. Armonk, NY: IBM Corp. All results are expressed as the mean ± standard deviation (SD). One-way analysis of variance (ANOVA) was performed to assess the effects of a single factor on multiple groups, and the Tukey test was used for post hoc testing. Survival curves were plotted using Kaplan-Meier estimates. A P-value ≤ 0.05 was considered statistically significant.
Results
Characteristics of DCs transduced with the lentivirus IL-10 vector
To generate IL-10 gene modified tolerogenic DCs, we transduced DCs with LV-GFP or LV-IL-10 overnight at 37℃ at a multiplicity of infection of 100 to obtain DC GFP -and DC LV-IL-10 . Examinations by fluorescence microscopy showed that the transduced DCs expressed GFP (Fig. 1A) . Our observations indicated that 49.61 ± 5.23% of DC GFP and 52.16 ± 6.24% of DC LV-IL-10 expressed GFP (P > 0.05) (Fig. 1B) . Moreover, FACS sorting results showed that 76.26 IL-10 mRNA expression on DC LV-IL-10 was significantly higher than that on DCs and DC GFP (P < 0.001) (Fig. 2A) . We also used ELISA to detect the levels of cytokines secreted by DCs, DC GFP and DC LV-IL-10 that had been activated with LPS and IFN-γ. As shown in Fig. 2B , the levels of IL-10 secreted by DC LV-IL-10 (923.65 ± 85.37 pg/mL) were significantly higher than the levels secreted by DCs (84.76 ± 7.19 pg/mL) and DC GFP (95.33 ± 9.17 pg/mL) (P < 0.01). However, there were no significant differences between the levels IL-6, TNF-α and IL-12p70 secreted by DC LV-IL-10 when compared with those levels secreted by DCs and DC GFP (P > 0.05).
Taken together, our data suggest that DCs can be successfully transduced with LV-IL-10 and maintain the morphology and phenotype of mature DCs; and at the same time, express high levels of IL-10. They therefore possess the properties needed to induce a population of Tr1 cells.
Induction of Tr1 cells by IL-10 gene modified DCs
To determine whether or not DC LV-IL-10 could induce Tr1 cells, naive CD4 + T cells were co-cultured with DCs, DC GFP or DC LV-IL-10 for 3 days in the presence of rmIL-2. The cells were then purified using a CD4 + T cell positive enrichment kit, and designated as T DC , T GFP or Tr1 cells respectively. We next analyzed whether DC LV-IL-10 -induced Tr1 cells express Tr1 cellassociated surface markers [10] and/or transcription factors [12] . As shown in Figs. 3A and 3B, 51.27 ± 3.86% of DC LV-IL-10 -induced Tr1 cells co-expressed CD49b and LAG-3. Moreover, they also expressed CD4, CD25, and IL-10, but not Foxp3. Next, the cytokines secreted by DC LV-IL-10 -induced T cells were analyzed by ELISA, and our results showed that Tr1 cells secreted significantly higher levels of IL-10 (1, 729.36 ± 185.79 pg/mL) than T DC (115.82 ± 13.29 pg/mL) and T GFP did (90.34 ± 11.83 pg/mL) (P < 0.001). Similarly, the levels of INF-γ secreted by Tr1 cells (1, 524.48 ± 168.65 pg/mL) were significantly higher than those .56 pg/mL) and T GFP (368 ± 65.79 pg/mL) (P < 0.01). However, the IL-2 and IL-4 levels secreted by Tr1 cells were not significantly different from those secreted by T DC and T GFP (P > 0.05) (Fig. 3C) . These data showed that DC LV-IL-10 co-cultured with naive CD4 + T cells could induce Tr1 cells that secrete high levels of IL-10 and IFN-γ, which are the main cytokines required for Tr1 cells to exert an immunosuppressive effect.
Tr1 cells were capable of inhibiting T-cell proliferation in vitro
To determine whether our induced Tr1 cells were anergic, T DC , T GFP or Tr1 cells were re-stimulated with DCs obtained from BALB/c mice. Our results showed that the Tr1 cells exhibited a significantly lower proliferative response when compared with T DC and T GFP (P < 0.01) (Fig. 4A) . This indicated that the Tr1 cells were Ag-specific anergic toward the antigen used for their generation. T cell proliferation when the Tr1/effector cell ratio was 4:1 (P < 0.01), 2:1 (P < 0.01) or 1:1 (P < 0.05). The strongest suppressive effect was obtained when the ratio was 4:1, and no suppressive effect was observed when the Tr1 to effector cell ratio was 1:2, indicating that Tr1 cells inhibited CD8 + and CD4 + T cell proliferation in a dose-dependent manner. To determine the role played by IL-10 in the suppressive effect of Tr1 cells, neutralizing anti-IL-10 and IFN-g antibodies were added to some of the cultures. When the ratio of T DC , T GFP or Tr1 cells to effector cells reached 4:1, the inhibitory effect of Tr1 cells was decreased > 90% by anti-IL-10 antibodies (P < 0.01), but not by anti-IFN-g antibodies (P > 0.05), indicating that IL-10 plays an important role in the suppressive activity of regulatory T cells.
MLR assays were performed to further confirm the immunosuppressive effect of DC LV-IL-10 -induced Tr1 cells. Irradiated (40 Gy) T DC , T GFP or Tr1 cells accompanied by effector Fig. 4D , Tr1 cells inhibited the MLR in a dose-dependent manner. The strongest suppressive effect was obtained when the ratio of Tr1 to effector cells was 4:1 (P < 0.01), and no suppressive effect was found when the Tr1 to effector cell ratio was 1:2 (P > 0.05).
Taken together, our data suggest that the DC LV-IL-10 -induced Tr1 cells were Ag-specific anergic, and capable of inhibiting CD8
+ and CD4 + T cell proliferation and the MLR in vitro.
DC LV-IL-10 -induced Tr1 cells induced transplant tolerance after an allogeneic bone marrow transplantation
We next investigated whether DC LV-IL-10 -induced Tr1 cells could inhibit alloreactivity and induce transplant-tolerance in vivo. Recipient BALB/c mice were given a lethal dose of radiation, and then infused with BMCs and SCs obtained from donor C57BL/6 mice with or without accompanying DC LV-IL-10 -induced Tr1 cells. The transplanted mice were monitored for signs and symptoms of GVHD. As shown in Fig. 5A , the GVHD scores of mice which received BM + T + Tr1 cells were significantly lower from day 6 onwards when compared with the GVHD scores of the control mice (P < 0.01).
Histopathological analyses of tissue sections revealed that the control mice displayed more obvious signs of GVHD in specimens of their skin, intestine, liver, and lung tissue on day 14 after the BMT, when compared with mice in the Tr1-treated groups (Fig. 5B) . We also used pathology scores to confirm the effect of a Tr1 cell infusion on GVHD. As shown in Fig. 5C , the histopathological GVHD scores of mice which received BM + T + Tr1 cells were significantly lower than those of the control mice with regards to skin, small intestine, liver, and lung damage (all P-values < 0.05). Furthermore, it appeared that the GVHD scores of mice which received a high dose of Tr1 cells (4 × 10 6 ) were lower than those of mice which received a low dose (2 × 10 6 ) of Tr1 cells. However, this difference was not statistically significant (P > 0.05). Our data also suggest that an infusion of Tr1 cells prolonged the mean survival time of the transplanted mice. As shown in Fig. 6 , the mean survival time of mice infused with BM + T was 28.7 ± 1.02 d, which was significantly less than the mean survival time of mice which received BM +T + Tr1 cells (2 × 10 6 ) (39.5 ± 3.02 d) (P < 0.05), as well as the mice which received BM + T + Tr1 cells (4 × 10 6 ) (mean survival time point not reached) (P < 0.01). At 50 days post-transplantation, 75% of the BALB/c mice that received BM + T + Tr1 cells (4 × 10 6 ) remained alive, whereas only 40% of the mice that received BM + T + Tr1 cells (2 × 10 6 ) were still alive (P < 0.05), indicating that infusing greater numbers of Tr1 cells could further increase the survival time of BMC-transplanted mice.
Discussion
Tregs play a crucial role in the induction of peripheral tolerance to self and foreign antigens, and can potentially be developed as a therapeutic tool to promote or restore immune tolerance in patients who have received a transplant or have inflammatory or [17, 23] . Adaptive Tr1 cells are generated peripherally when dendritic cells present antigens to naive T cells; after which, the resultant adaptive Tr1 cells can assume a variety of phenotypes depending upon the conditions under which they are induced. It was previously shown that IL-10 and TGF-b-secreting Tr1 cells are generated upon Ag-presentation by immature DCs and also DCs that express IL-10 or TGF-b [24, 25] .
In this study, 78.39 ± 8.67% of DC LV-IL-10 sorted by FACS displayed morphologic and phenotypic characteristics typical of mature DCs. The IL-10 levels secreted by DC LV-IL-10 were higher than those secreted by DCs and DC GFP , and were satisfactory to induce a population of Tr1 cells [17] . Subsequently, we incubated naive CD4 + T cells with irradiated DC LV-IL-10 for 3 days, and found that 51.27 ± 3.86% of the purified T cells co-expressed CD49b and LAG-3, which are Tr1-related phenotypic markers [10] . Moreover, the Tr1 cells also expressed CD4, CD25 and IL-10, but not Foxp3 [12] . After re-stimulation in vitro, the Tr1 cells secreted high levels of IL-10 and IFN-γ, but only low levels IL-4 and IL-2. Taken together, our data suggest that LV-IL-10-transduced DCs are capable of stimulating the differentiation of naive CD4+ T cells into Tr1 cells that secrete the characteristic cytokines, IL-10 and IFN-γ [10, 26, 27] . Notably, when Tr1 cells were re-stimulated with the antigen used for their generation, the cells exhibited a significant hyporesponsiveness to re-stimulation. That result indicated that the Tr1 cells were Ag-specific anergic toward the antigen used for their priming [13] .
Tregs can suppress the proliferation of CD8 + and CD4 + T cells in part, by inhibiting IL-2 production, or reducing the effector function of T cells [5, 28, 29] . They can also transfer their suppressive properties to other CD4 + T cells, resulting in new CD4 suppressive T cells or T cell anergy [30] [31] [32] . Additionally, Tregs can downregulate MHC II, CD80, and CD86 expression on DCs and induce indoleamine 2, 3-dioxygenase (IDO) expression [33, 34] .
We performed Tr1-mediated T cell proliferation and MLR inhibition assays to determine whether the Tr1 cells suppressed CD8 + or CD4 + T cells. Our results showed that DC LV-IL-10 induced Tr1 cells could significantly suppress both CD8 + T and CD4 + T cell proliferation and the MLR in vitro in dose-dependent manners. Furthermore, addition of anti-IL-10, but not anti-IFN-g antibodies to the CD8 + T and CD4 + T cell cultures assays caused Tr1 cell proliferation to be inhibited by > 90%, suggesting that IL-10 is crucial for the activity of these regulatory T cells.
IL-10 is an immune regulatory cytokine that is indispensable for controlling inflammation, downregulating immune responses, and inducing tolerance [35] . Importantly, IL-10 induces the differentiation of Tr1 cells and long-lasting Ag-specific T-cell anergy in both humans [36] and mice [37] . Although IL-10 is essential for inducing Tr1 cells, when used in vitro, its function requires the presence of APCs [15, 38] . Some studies have also shown that T cell priming drives the differentiation of Tr1 cells in vitro by immature DC or DCs rendered tolerogenic by biologic or pharmacologic agents [38] .
The suppressive function of natural regulatory T cells is Ag-nonspecific [39] . However, we previously demonstrated that CD4 + CD25 + Tregs can acquire Ag-specificity via the uptake of Ag-specific DC-released exosomes (EXO) [12] . In a previous study, CD4
+ CD25 + Tregs with acquired pMHC I complexes (Ag-specificity) displayed a greater ability to inhibit Ag-specific immunity than Tregs without pMHC I [12] . Yamazaki et al [40] . demonstrated that under in vitro conditions, either Ag-specific DCs or non-specific DCs administered in combination with IL-2 could stimulate the proliferation of fully functional CD4 + CD25 + Tregs. This suggests that cognate Ag-unrelated CD4 + CD25 + Tregs in peripheral blood can also be expanded by incubation with DCs presenting cognate Ag, and that the pMHC I and pMHC II complexes acquired from those DCs by the CD4 + Tregs may produce some degree of Ag-specificity. Sanchez-Fueyo et al [25] . demonstrated that Ag-specific Tregs derived from T cell receptor (TCR)-transgenic mice inhibit immune responses more effectively than do polyclonal Tregs obtained from non-transgenic mice. Furthermore, Ag-specific Tregs have been shown to be more effective than polyclonal Tregs in preventing graft rejection in humanized pre-clinical models [41, 42] . Therefore, we speculated that during induction of Tr1 cells, DC LV-IL-10 derived from recipient mice might present the pMHC I and pMHC II complexes of recipient mice to Tr1 cells derived from donor mice. These Tr1 cells might then suppress the response of donor T cells towards their specific Ag, and thereby induce immune tolerance of donor T cells after an allogeneic BMT. In our study, the recipient mice were infused with BMCs and SCs obtained from donor mice to induce GVHD after a lethal dose of radiation. Infusing recipient mice with DC LV-IL-10 -induced donor mouse Tr1 cells remarkably reduced the severity of GVHD. This was shown by the significantly lower histopathological and clinical GVHD scores among the mice treated with Tr1 cells rather than control cells. Furthermore, the transplanted mice in the Tr1-infused groups survived significantly longer than mice in the control group. Additionally, mice infused with 4 × 10 6 Tr1 cells survived longer than mice infused with 2 × 10 6 Tr1 cells, indicating that the suppressive effect of Tr1 cells was dose-dependent manner. In conclusion, ex vivo induction and expansion of Tr1 cells achieved by co-culturing IL-10 gene-modified DCs with naive CD4 + T cells is a promising approach for inducing Tr1 cells, and may be used to facilitate the development of cellular therapies for graft versus-host disease and other autoimmune diseases.
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